Drug Trial Radar · NCT06719310
Phase Ib/IIa Clinical Study of ACC017 Tablets
Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
36
Actual
Start
Aug 28, 2024
Primary completion
Apr 28, 2025
Study completion Apr 28, 2025
Sponsor
- Lead sponsor
- Jiangsu Aidea Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Chengdu Aidea Pharmaceutical Technology Co., Ltd
- First posted
- Dec 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ACC017 is an integrase inhibitor that will be evaluated for the treatment of HIV infection. This phase Ib/IIa, randomized, double-blind, parallel, dose ranging, placebo-controlled 'proof of concept' study is designed to evaluate the safety, tolerability, pharmacokinetics and antiviral effect of ACC017 monotherapy and combined with FTC/TAF by sequency versus placebo in treatment-naïve HIV-1 infected adults. This study includes two stages, stage one is a single dose escalation, and all subjects will be co-administrated with FTC/TAF at 200 mg/25 mg on stage two. The study consists of a screening visit, baseline period, monotherapy period, and combination therapy period. Total 36 subjects will be randomized in a 5:1 ratio to receive one of three doses of ACC017 or placebo lasting for 10 days for monotherapy followed by 18 days for combination therapy.
Conditions
- Infection, Human Immunodeficiency Virus
Interventions
ACC017+FTC/TAFDrug
ACC017+FTC/TAF
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Report the incidence, severity and seriousness of adverse events, and the relationship between drug and AETime frame: Day 1- Day 11
- HIV-1 RNA viral load change from baselineTime frame: Day 11
- Proportion of patients with HIV-1 RNA viral load <50 copies/mLTime frame: Day 29
- Pharmacokinetics parameter: Cτ,ssTime frame: Day 10, Day 29
- Pharmacokinetics parameter: Cmin,ssTime frame: Day 10
- Pharmacokinetics parameter: Cmax,ssTime frame: Day 10
- Pharmacokinetics parameter: AUC0-τ,ssTime frame: Day 1- Day 10
- Pharmacokinetics parameter: Tmax,ssTime frame: Day 1-Day 10
- Pharmacokinetics parameter: MRT0-τ,ssTime frame: Day 1-Day 10
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Ditan Hospital, Capital Medical University
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.